ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 313

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

William Torelli1, James Ross 2, Thomas Quinn 2, Kourtney Erickson 1, Andrea Soliman 1 and Attiya Harit 3, 1Lehigh Valley Health Network, Allentown, PA, 2lehigh valley health network, allentown, 3lehigh valley health organization, allentown

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: hyperlipidemia, Tocilizumab, tofacitinib and baricitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab are biologics (IL6 inhibitors) for the management of inflammatory arthritis, and giant cell arteritis. Aforementioned drugs elevate total cholesterol and LDL levels. Primary aim is to assess compliance for screening and treatment per guidelines of the American College of Rheumatology (ACR) (ARP Practice Committee, 2017) for hyperlipidemia in patients receiving tofacitinib, tocilizumab, sarilumab, and baricitinib at Lehigh Valley Health Network (LVHN).

Methods: Data reviewed on 146 patients within LVHN, from December 2018 to April 2018. Subjects were retrieved from Epic by searching for orders for the drugs of interest. Manual Chart Review was utilized to determine: age, gender, ethnicity, pathology, medication, steroid dose, additional DMARDs, medication duration, date of drug initiation, previous statin, baseline lipid panel, frequency of lipid screenings, and statin initiated.

Results: Table 1 shows demographic and clinical variables of the charts reviewed. Medications used were the following: tofacitinib (64%), tocilizumab (27%), sarilumab (8%), and baricitinib (0.68%).  Patients examined were afflicted with the following disease processes: RA (90%), GCA (4%), SpA (4%), and JIA (2%). Prior to the intervention 29% of patients were on a statin, and 28% had indications for a statin yet were not prescribed one. Additionally, only 17% of patients had a proper baseline lipid screening 4-8 weeks after starting the drug. Only 13% of patient had lipid screenings every 6 months after institution of the drug. Mean age was 56 years old, with 77% female, and average duration on drug of interest was 760.5 days.   

Conclusion: According to ACR guidelines, laboratory monitoring for patients on JAK and IL6 inhibition is recommended due to treatment related changes in neutrophils, platelets, lipids, and liver specific enzymes (ARP Practice Committee, 2017). Additionally, British Society for Rheumatology (BSR) advocates for baseline lipid screenings, and rescreening every 3 months  (Malaviya, 2014). After analyzing patients in LVHN there is room for improvement. Twenty eight percent of patients in the project have an indication for statin therapy, and are not being treated.  Eighty two percent of patients lacked baseline lipid screening 4-8 weeks after starting JAK and IL6 inhibition. An intervention educating rheumatology providers on guidelines for these medications, and options for managing subjects with lipid lowering agents will follow initial data assessment. Data will be re-collected and assessed for improvement in guideline compliance and treatment following the intervention. After the intervention we expect to see increased compliance with lipid screening and management with patients on the drugs of interest within LVHN.


flow chart 1

Figure 1.


table 1.

Table 1.


Figure 2.

Figure 2.


Disclosure: W. Torelli, None; J. Ross, None; T. Quinn, None; K. Erickson, None; A. Soliman, None; A. Harit, None.

To cite this abstract in AMA style:

Torelli W, Ross J, Quinn T, Erickson K, Soliman A, Harit A. Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/screening-and-treating-hyperlipidemia-in-patients-on-tofacitinib-tocilizumab-sarilumab-and-baricitinib/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-and-treating-hyperlipidemia-in-patients-on-tofacitinib-tocilizumab-sarilumab-and-baricitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences